|
|
||||||||
ORIGINAL RESEARCH |

From the *Division of Maternal-Fetal Medicine, Department of Obstetrics/Gynecology, and
Division of Neonatology, Department of Pediatrics, Center for Research in Women's Health, University of Alabama at Birmingham, Birmingham, Alabama.
Address reprint requests to: Patrick S. Ramsey, MD, Division of Maternal-Fetal Medicine, Department of Obstetrics/Gynecology, 446 Old Hillman Building, 619 19th Street South, Birmingham, AL; e-mail: ramsey_patrick{at}hotmail.com.
| ABSTRACT |
|---|
|
|
|---|
METHODS: We reviewed maternal and neonatal outcomes of women with PROM 24 weeks or more that resulted in delivery at less than 37 weeks at our institution from August 1998 to August 2000. Standardized management included the use of antibiotics, betamethasone at less than 32 weeks, and expectant management until 24 weeks or more. Outcomes evaluated included neonatal mortality, composite major and minor neonatal morbidity, individual major and minor neonatal morbidity rates, maternal infection morbidity, and maternal and neonatal length of stay. Gestational agespecific maternal and neonatal outcomes were compared with a referent group of pregnancies complicated by preterm PROM that delivered between 36 0/7 and 36 6/7 weeks of gestation.
RESULTS: During the study interval, 430 women with preterm PROM were identified. Composite major neonatal morbidity was significantly higher among pregnancies delivered at 33 weeks of gestation or less after preterm PROM as compared with those who delivered at 36 weeks. Composite neonatal minor morbidity was significantly higher among pregnancies delivered at 34 weeks or less after preterm PROM as compared with those who delivered at 36 weeks. However, there was no improvement in the composite major and minor neonatal morbidity rates for those pregnancies delivered beyond 34 weeks of gestation. Both maternal and infant length of stay were significantly longer for cases of preterm PROM delivered at 34 weeks or less as compared with those who delivered at 36 weeks.
CONCLUSION: Our findings suggest that expectant management of women at 34 weeks and beyond is of limited benefit.
LEVEL OF EVIDENCE: II-3
During the past decade a growing body of evidence has emerged associating upper genital tract infection with both spontaneous preterm delivery and preterm PROM.58 A number of studies have demonstrated that this occult intrauterine infection as well as clinical chorioamnionitis may be associated with the subsequent development of adverse neonatal outcomes such as neonatal death, periventricular leukomalacia, intraventricular hemorrhage, cerebral palsy, and bronchopulmonary dysplasia.922 Upper genital tract infection may result in an indolent inflammatory response, eliciting the production of a wide array of proinflammatory mediators that can lead to injury to the fetal central nervous system and lung.17 Thus, the development of occult or clinically evident intrauterine infection may pose significant neonatal risks. Given that expectant management of preterm PROM entails close surveillance for the development of chorioamnionitis, with delivery implemented when it is diagnosed, the fetus is inherently exposed to an environment in which an array of inflammation and proinflammatory cytokines are present.
The decision to abandon further expectant management of women with preterm PROM in favor of delivery requires a close assessment of the potential risks related to the development of intrauterine infection in those pregnancies expectantly managed compared with the gestational agerelated risks for neonatal morbidity and mortality related to intentional delivery. To address this important issue, we conducted a comprehensive review of neonatal and maternal outcomes of all pregnancies complicated by preterm PROM that were recently managed at our institution, using a standardized management protocol. These data were sought to provide important information regarding neonatal and maternal morbidity and mortality rates in pregnancies complicated by preterm PROM and determine whether there is an optimal delivery gestational age.
| MATERIALS AND METHODS |
|---|
|
|
|---|
All women in this investigation were managed under a standardized protocol that included inpatient expectant management for all cases of preterm PROM less than 34 weeks of gestation (in the absence of active labor, chorioamnionitis, and fetal compromise), administration of prophylactic antibiotics (azithromycin 1 g on presentation, with repeated dosing once on day 5; ampicillin and amoxicillininitially, intravenous ampicillin 2 g every 6 hours for 1224 hours followed by amoxicillin 250 mg orally every 8 hours for 10 days), and administration of betamethasone 12 mg intramuscularly (2 doses 24 hours apart) for those pregnancies less than 32 weeks. Maternal and fetal status was closely monitored for development of chorioamnionitis, labor, or fetal compromise. Vaginal amniotic fluid pool specimens were collected for the determination of the presence of phosphatidylglycerol on all women beginning at 32 weeks of gestation and repeated weekly if immature until delivery. Expectant management was abandoned and delivery expedited if any of the following criteria were noted: 1) chorioamnionitis, 2) active labor, 3) fetal compromise, 4) presence of phosphatidylglycerol in vaginal pool amniotic fluid specimen, or 5) gestational age 34 weeks or more. Pregnancy dating was established according to standardized institutional guidelines.
All maternal and neonatal medical records were reviewed and outcome data collected using standardized definitions. Specific outcomes evaluated included neonatal mortality, composite major and minor neonatal morbidity (defined below), individual major and minor neonatal morbidity rates, maternal infection morbidity (endometritis or chorioamnionitis), and maternal and neonatal length of stay. Composite neonatal major morbidity was defined as the presence of any of the following: intraventricular hemorrhage, respiratory distress syndrome, intubation, bronchopulmonary dysplasia, sepsis, seizure, necrotizing enterocolitis, bowel perforation, retinopathy of prematurity, meningitis, pneumonia or primary pulmonary hypertension, patent ductus arteriosis, or retinopathy of prematurity). Composite neonatal minor morbidity was defined as the presence of any of the following: hyperbilirubinemia, transient tachypnea of the newborn, or metabolic disturbances (hyper- or hypoglycemia or hyper- or hyponatremia).
Outcome data for each gestational age were statistically compared with the respective outcome for those preterm PROM pregnancies that delivered at 36 0/7 to 36 6/7 weeks of gestation. Statistical analyses included the Student t test,
2, and Fisher exact test where appropriate.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Despite the pivotal importance of accurate data regarding major and minor neonatal morbidities in pregnancies complicated by preterm PROM, few studies have attempted fully to characterize these morbidities in an attempt to identify an optimal gestational age for delivery of pregnancies complicated by preterm PROM. In the current study we have provided a comprehensive assessment of maternal and neonatal major and minor morbidities in women with preterm PROM who weremanaged under a standardized management protocol. We have demonstrated no improvement in the composite major and minor neonatal morbidity rates for those pregnancies delivered beyond 34 weeks of gestation. Both maternal and neonatal length of hospital stay were also similar for infants delivered beyond 34 weeks of gestation in our investigation. Our findings are similar to those reported by Jothivijayarani et al.26 These investigators characterized maternal and neonatal outcomes of 79 women with preterm PROM between 32 and 36 weeks of gestation, noting a marked decrease in the incidence of respiratory distress syndrome beyond 34 weeks of gestation.26 In addition, infant length of hospital stay and the incidence of hyperbilirubinemia decreased significantly after 34 weeks of gestation. Neerhoff et al,27 in a study of 236 women with preterm PROM between 32 and 36 weeks of gestation, noted similar decreases in infant length of hospital stay and the incidence of hyperbilirubinemia in infants born at 34 weeks of gestation or more when compared with infants born at less than 34 weeks of gestation. Our data question the benefit of continued expectant management beyond 34 weeks of gestation with modern obstetric and neonatal management.
Data from our investigation, and those from others, clearly call for further research to elucidate the optimal delivery gestational age for women who develop preterm PROM between 30 and 36 weeks of gestation. A large randomized trial of induction compared with expectant management of women with preterm PROM diagnosed beyond 30 to 33 weeks of gestation is needed to adequately address important issues related to major and minor, as well as long-term, maternal and infant outcomes.
| Footnotes |
|---|
Received June 20, 2004. Received in revised form August 19, 2004. Accepted September 4, 2004.
doi:10.1097/01.AOG.0000147841.79428.4b
| REFERENCES |
|---|
|
|
|---|
2. Garite TJ. Management of premature rupture of membranes. Clin Perinatol 2001;28:8374.[Medline]
3. Ohlsson A. Treatment of preterm premature rupture of the membranes: a meta-analysis. Am J Obstet Gynecol 1989;160:890906.[Medline]
4. Capeless EL, Mead PB. Management of preterm premature rupture of membranes: lack of a national consensus. Am J Obstet Gynecol 1987;157:112.[Medline]
5. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342:15007.
6. Gibbs RS, Romero R, Hillier SI, Eschenbach DA, Sweet RL. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992;166:151528.[Medline]
7. Asrat T. Intra-amniotic infection in patients with preterm prelabor rupture of membranes: pathophysiology, detection, and management. Clin Perinatol 2001;28:73551.[Medline]
8. Arias F, Victoria A, Cho K, Kraus F. Placental histopathology and clinical characteristics of patients with preterm premature rupture of membranes. Obstet Gynecol 1997;89:26571.[Abstract]
9. Garite TJ, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol 1982;59:53945.
10. Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi JH, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997;177:1926.[Medline]
11. Yoon BH, Romero R, Yang SH, Jun JK, Kim IO, Choi JH, et al. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol 1996;174:143340.[Medline]
12. Yoon BH, Romero R, Park JS, Kim CJ, Choi JH, Han TR. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000;182:67581.[Medline]
13. Redline RW, Wilson-Costello D, Borawski E, Fanaroff AA, Hack M. Placental lesions associated with neurologic impairment and cerebral palsy in very low-birth-weight infants. Arch Pathol Lab Med 1998;122:10918.[Medline]
14. Vigneswaren R. Infection and preterm birth: evidence of a common causal relationship with bronchopulmonary dysplasia and cerebral palsy. J Paediatr Child Health 2000;36:2936.[Medline]
15. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:2105.
16. Yoon BH, Romero R, Kim KS, Park JS, Ki SH, Kim BI, et al. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1999;181:7739.[Medline]
17. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998;53:8194.[Medline]
18. Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998;44:66575.[Medline]
19. Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA 1997;278:20711.[Abstract]
20. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997;42:18.[Medline]
21. Nelson KB, Ellenberg JH. Antecedents of cerebral palsy: multivariate analysis of risk. N Engl J Med 1986;315:816.[Abstract]
22. Gaudet LM, Smith GN. Cerebral palsy and chorioamnionitis: The inflammatory cytokine link. Obstet Gynecol Surv 2001;56:4336.[Medline]
23. Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. Am J Obstet Gynecol 1993;169:77582.[Medline]
24. Cox SM, Leveno KJ. Intentional delivery versus expectant management with preterm ruptured membranes at 3034 weeks' gestation. Obstet Gynecol 1995;86:8759.[Abstract]
25. Naef RW, Allbert JR, Ross EL, Weber M, Martin RW, Morrison JC. Premature rupture of membranes at 34 to 37 weeks' gestation: aggressive versus conservative management. Am J Obstet Gynecol 1998;178:12630.[Medline]
26. Jothivijayarani A, Hansen W, Zimmerman B. Preterm premature rupture of membranes at 32 to 36 weeks of gestation: neonatal and maternal outcomes. J Soc Gynecol Investig 2002;9:98A.
27. Neerhof MG, Cravello C, Haney EI, Silver RK. Timing of labor induction after premature rupture of membranes between 32 and 36 weeks' gestation. Am J Obstet Gynecol 1999;180:34952.[Medline]
This article has been cited by other articles:
![]() |
J. C. Pasquier, E. Bujold, and G. Mellie Preterm Premature Rupture of Membranes: Is There an Optimal Gestational Age for Delivery? Obstet. Gynecol., June 1, 2005; 105(6): 1484 - 1485. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |